Update on group A streptococcal vaccine development.
Journal
Current opinion in infectious diseases
ISSN: 1473-6527
Titre abrégé: Curr Opin Infect Dis
Pays: United States
ID NLM: 8809878
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
pubmed:
19
4
2020
medline:
13
4
2021
entrez:
19
4
2020
Statut:
ppublish
Résumé
There is a global need for well tolerated, effective, and affordable vaccines to prevent group A streptococcal infections and their most serious complications. The aim of this review is to highlight the recent progress in the identification of promising vaccine antigens and new approaches to vaccine design that address the complexities of group A streptococcal pathogenesis and epidemiology. Combination vaccines containing multiple shared, cross-protective antigens have proven efficacious in mouse and nonhuman primate models of infection. The development of complex multivalent M protein-based vaccines is continuing and several have progressed through early-stage human clinical trials. Formulations of vaccines containing universal T-cell epitopes, toll-like receptor agonists, and other adjuvants more potent than alum have been shown to enhance protective immunogenicity. Although the group A streptococcal vaccine antigen landscape is populated with a number of potential candidates, the clinical development of vaccines has been impeded by a number of factors. There are now concerted global efforts to raise awareness about the need for group A streptococcal vaccines and to support progress toward eventual commercialization and licensure. Preclinical antigen discovery, vaccine formulation, and efficacy studies in animal models have progressed significantly in recent years. There is now a need to move promising candidates through the clinical development pathway to establish their efficacy in preventing group A streptococcal infections and their complications.
Identifiants
pubmed: 32304470
doi: 10.1097/QCO.0000000000000644
pmc: PMC7326309
mid: NIHMS1602405
pii: 00001432-202006000-00005
doi:
Substances chimiques
Adjuvants, Immunologic
0
Antigens, Bacterial
0
Streptococcal Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
244-250Subventions
Organisme : NIAID NIH HHS
ID : R01 AI132117
Pays : United States
Références
Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5:685–694.
Collaborators GMaCoD. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385:117–171.
O’Loughlin RE, Roberson A, Cieslak PR, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000–2004. Clin Infect Dis 2007; 45:853–862.
Watkins DA, Johnson CO, Colquhoun SM, et al. Global, Regional, and National Burden of Rheumatic Heart Disease, 1990–2015. N Engl J Med 2017; 377:713–722.
Young DC. Failure of type-specific Streptococcus pyogenes vaccine to prevent respiratory infections. US Navy Med Bull 1946; (46):709.
Wolfe CK Jr, Hayashi JA, Walsh G, Barkulis SS. Type-specific antibody response in man to injections of cell walls and M protein from group A, type 14 streptococci. J Lab Clin Med 1963; 61:459–468.
Potter EV, Stollerman GH, Siegel AC. Recall of type specific antibodies in man by injections of streptococcal cell walls. J Clin Invest 1962; 41:301–310.
Massell BF, Michael JG, Amezcua J, Siner M. Secondary and apparent primary antibody responses after group A streptococcal vaccination of 21 children. Appl Microbiol 1968; 16:509–518.
Massell BF, Honikman LH, Amezcua J. Rheumatic fever following streptococcal vaccination. Report of three cases. JAMA 1969; 207:1115–1119.
Fox EN, Waldman RH, Wittner MK, et al. Protective study with a group A streptococcal M protein vaccine. Infectivity challenge of human volunteers. J Clin Invest 1973; 52:1885–1892.
Polly SM, Waldman RH, High P, et al. Protective studies with a group A streptococcal M protein vaccine. II. Challenge of volunteers after local immunization in the upper respiratory tract. J Infect Dis 1975; 131:217–224.
Beachey EH, Stollerman GH, Johnson RH, et al. Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein. J Exp Med 1979; 150:862–877.
Maclennan AP. The production of capsules, hyaluronic acid and hyaluronidase by group A and group C Streptococci. J Gen Microbiol 1956; 14:134–142.
Micoli F, Constantino P, Adamo R. Potential targets for next generation antimicrobial glycoconjugate vaccines. FEMS Microbiol Rev 2018; 42:388–423.
Mistou M-Y, Sutcliffe IA, van Sorge NM. Bacterial glycobiology: rhamnose-containing cell wall polysaccharides in Gram-positive bacteria. FEMS Microbiol Rev 2016; 40:464–479.
Edgar RJ, van Hensbergen VP, Ruda A, et al. Discovery of glycerol phosphate modification on streptococcal rhamnose polysaccharides. Nat Chem Biol 2019; 15:463–471.
Sabharwal H, Michon F, Nelson D, et al. Group A Streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection. J Infect Dis 2006; 193:129–135.
Malkiel S, Liao L, Cunningham MW, Diamond B. T-cell-dependent antibody response to the cominant epitope of Streptococcal polysaccharide, N-acetyl-glucosamine, is cross-reactive with cardiac myosin. Infect Immun 2000; 68:5803–5808.
van Sorge NM, Cole JN, Kuipers K, et al. The classical lancefield antigen of group a Streptococcus is a virulence determinant with implications for vaccine design. Cell Host Microbe 2014; 15:729–740.
Rivera-Hernandez T, Pandey M, Henningham A, et al. Differing efficacies of lead group A Streptococcal vaccine candidates and full-length M protein in cutaneous and invasive disease models. mBio 2016; 7:e00618-16.
Walker MJ, Barnett TC, McArthur JD, et al. Disease manifestations and pathogenic mechanisms of group A Streptococcus. Clin Microbiol Rev 2014; 27:264–301.
Henningham A, Gillen CM, Walker MJ. Chhatwal GS. Group A Streptococcal vaccine candidates: potential for the development of a human vaccine. Host-pathogen interactions in streptococcal diseases. 368. Heidelberg: Springer; 2012. 207–242.
Davies MR, McIntyre L, Mutreja A, et al. Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics. Nat Genet 2019; 51:1035–1043.
Moreland NJ, Waddington CS, Williamson DA, et al. Working towards a grup A Streptococcal vaccine: report of a collaborative trans-tasman workshop. Vaccine 2014; 32:3713–3720.
Bensi G, Mora M, Tuscano G, et al. Multi high-throughput approach for highly selective identification of vaccine candidates: the group A Streptococcus case. Mol Cell Proteom 2012; 11: M111.015693.
Rivera-Hernandez T, Rhyme MS, Cork AJ, et al. Vaccine-induced Th1-type response protects against invasive group A streptococcus infection in the absence of opsonizing antibodies. mBio 2020; 11: pii: e00122-20.
pii: e00122-20
Rivera-Hernandez T, Carnathan DG, Jones S, et al. An experimental group A Streptococcus vaccine that reduces pharyngitis and tonsilitis in a nonhuman primate model. mBio 2019; 10:e00693-19.
Reglinski M, Gierula M, Lynskey NN, et al. Identification of the Streptococcus pyogenes surface antigens recognised by pooled human immunoglobulin. Sci Rep 2015; 5:15825.
Reglinski M, Lynskey NN, Jung Choi Y, et al. Development of a multicomponent vaccine for Streptococcus pyogenes based on the antigenic targets of IVIG. J Infect 2016; 72:450–459.
Bi S, Xu M, Zhou Y, et al. A multicomponent vaccine provides immunity against local and systemic infections by group A Streptococcus across serotypes. mBio. 10(6):e02600–19.
CDC Streptococcal Reference Page. Available from: ftp://ftp.cdc.gov/pub/infectious_diseases/biotech/tstransl/.
Dale JB, Chiang EY, Lederer JW. Recombinant tetravalent group A streptococcal M protein vaccine. J Immunol 1993; 151:2188–2194.
Dale JB, Simmons M, Chiang EC, Chiang EY. Recombinant, octavalent group A streptococcal M protein vaccine. Vaccine 1996; 14:944–948.
Dale JB. Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments. Vaccine 1999; 17:193–200.
Hu MC, Walls MA, Stroop SD, et al. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002; 70:2171–2177.
Dale JB, Penfound TA, Chiang EY, Walton WJ. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against nonvaccine serotypes of group A streptococci. Vaccine 2011; 29:8175–8178.
Pastural E, McNeil SA, MacKinnon-Cameron D, et al. Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: a randomized, controlled phase I study. Vaccine 2020; 38:1384–1392.
Wozniak A, Scioscia N, Garcia PC, et al. Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus. Microbiol Immunol 2018; 62:395–404.
Garcia PC, Paillavil BA, Scioscia N, et al. Clinical and microbiological response of mice to intranasal inoculation with Lactococcus lactis expressing Group A Streptococcus antigens, to be used as an antistreptococcal vaccine. Microbiol Immunol 2018; 62:711–719.
Steer AC, Law I, Matatolu L, et al. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis 2009; 9:611–616.
Giffard PM, Tong SYC, Holt DC, et al. Concerns for efficacy of a 30-valent M-protein-based Streptococcus pyogenes vaccine in regions with high rates of rheumatic heart disease. PLoS Negl Trop Dis 2019; 13:e0007511.
Abraham T, Sistla S. Decoding the molecular epidemiology of group A streptococcus - an Indian perspective. J Med Microbiol 2019; 68:1059–1071.
Sanderson-Smith M, De Oliveira DM, Guglielmini J, et al. A systematic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development. J Infect Dis 2014; 210:1325–1338.
Dale JB, Smeesters PR, Courtney HS, et al. Structure-based design of broadly protective group a streptococcal M protein-based vaccines. Vaccine 2017; 35:19–26.
Frost HR, Laho D, Sanderson-Smith ML, et al. Immune cross-opsonization within emm clusters following group a streptococcus skin infection: broadening the scope of type-specific immunity. Clin Infect Dis 2017; 65:1523–1531.
Buffalo CZ, Bahn-Suh AJ, Hirakis SP, et al. Conserved patterns hidden within group A Streptococcus M protein hypervariability recognize human C4b-binding protein. Nat Microbiol 2016; 1:16155.
Ghosh P. Variation, Indispensability, and Masking in the M protein. Trends Microbiol 2018; 26:132–144.
Good MF, Pandey M, Batzloff MR, Tyrrell GJ. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci. Expert Rev Vaccines 2015; 14:1459–1470.
Guilherme L, Fae KC, Higa F, et al. Towards a vaccine against rheumatic fever. Clin Dev Immunol 2006; 13 (2–4):125–132.
Postol E, Sa-Rocha LC, Sampaio RO, et al. Group A streptococcus adsorbed vaccine: repeated intramuscular dose toxicity test in minipigs. Sci Rep 2019; 9:9733.
Batzloff MR, Hayman WA, Davies MR, et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis 2003; 187:1598–1608.
Batzloff MR, Hartas J, Zeng W, et al. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal Peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group a streptococcus challenge and reduces throat colonization. J Infect Dis 2006; 194:325–330.
Campbell PT, Frost H, Smeesters PR, et al. Investigation of group A Streptococcus immune responses in an endemic setting, with a particular focus on J8. Vaccine 2018; 36:7618–7624.
Sekuloski S, Batzloff MR, Griffin P, et al. Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial. PLoS One 2018; 13:e0198658.
Nevagi RJ, Dai W, Khalil ZG, et al. Structure-activity relationship of group A streptococcus lipopeptide vaccine candidates in trimethyl chitosan-based self-adjuvanting delivery system. Eur J Med Chem 2019; 179:100–108.
Nordstrom T, Pandey M, Calcutt A, et al. Enhancing vaccine efficacy by engineering a complex synthetic peptide to become a super immunogen. J Immunol 2017; 199:2794–2802.
Schulze K, Ebensen T, Chandrudu S, et al. Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection. Nanomedicine 2017; 13:2463–2474.
Xu Z, Rivera-Hernandez T, Chatterjee O, et al. Semisynthetic, self-adjuvanting vaccine development: Efficient, site-specific sortase A-mediated conjugation of Toll-like receptor 2 ligand FSL-1 to recombinant protein antigens under native conditions and application to a model group A streptococcal vaccine. J Control Release 2019; 317:96–108.
World Health Organization. Available from: https://www.who.int/ncds/management/rheumatic-heart-disease-resolution/en/2018.
Vekemans J, Gouvea-Reis F, Kim JH, et al. The path to group A Streptococcus vaccines: WHO research and development technology roadmap and preferred product characteristics. Clin Infect Dis 2019; 69:877–883.
Osowicki J, Azzopardi KI, Baker C, et al. Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study. Vaccine 2019; 37:3485–3494.